Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDD-C in Relapsed Multiple Myeloma
NCT01078441Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2010
- Primary completion
- Feb 2014
- Modality
- Modified Peptides, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, pegylated liposomal doxorubicin, dexamethasone, cyclophosphamide in multiple myeloma (MM), sponsored by National Cancer Institute. Started Sep 2010; status: terminated.
02
Drugs
bortezomibpegylated liposomal doxorubicindexamethasonecyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01078441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01078441.